We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.

July 31, 2020

News You need - 3 Big Little Things

Announcements/News
Kate O'Reilly
&

It’s time for your monthly digital health news dose. We have looked back at three of the most noteworthy pieces of news from the last month and distilled what they mean for the industry and the key takeaways you should have on your radar. Interested in getting beyond the headlines? We’ve included three industry experts who can help you get behind these stories - just let us know if you’d like us to make the introduction!


Are we testing the right indications in the right places?

Snapshot of the Story

The Oxford University coronavirus vaccine being developed with AstraZeneca is being tested in Brazil and South Africa, as well as in the UK. Why? Because you need people with the disease to test it on. Having said that, according to a paper in Nature, of the 2,000 Covid-19 clinical trials registered around the world, more than 90 per cent are in ''wealthy'' countries, with China and India accounting for the bulk of the rest. Less affluent countries in Africa, Asia and Latin America barely get a look in. 

Why Is This Notable? 

  1. There have always been ethical questions about running trials in poorer or less developed countries because of the possible lack of people's awareness of rights, lack of regulatory rigor, and other social/ economic inequalities. So, suggesting that we ramp up testing of drugs in these nations can seem a bit controversial. 
  2. One of the things I have been concerned about during Covid-19 is that even if we do manage to develop a vaccine in record time, when will this actually reach masses in Africa and LATAM? There has been a history of medicines that are tested in rich countries taking years to reach poorer ones.
  3. Contrary to popular belief, many Asian and African countries have excellent clinical trial infrastructure and have built up expertise over the years to combat many epidemics, such as SARS and Ebola.  

Industry Implications

  1. What have we really tested, and will it work on the populations that need it most? 
  2. Testing in the right places for the right indications should be the best practice: let us not for example test malaria medication in Iceland. 
  3. On whom will the tested benefit first :Medication approval should always benefit the populations on whom they were trialled. Only seems fair, right? 
Pravin Jadhav
Pravin Jadhav
Senior Director, Innovation and Business Transformation, Corporate Projects
Otsuka Pharmaceutical Companies (U.S.)

Pravin has spearheaded a number of the R7D initiatives at his company, including optimizing trials with technology. He is very passionate about this topic.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

It isn't only just a DREAM

Snapshot of the story

Pear Therapeutics announced recruitment for a remote, 9-week insomnia treatment trial to collect real world data for a digital therapeutic (DREAM) back in February of this year. The study enrolled its first participant this week. This is an open-access, open-label, decentralized clinical trial to collect real-world evidence for PEAR-003A, a digital therapeutic delivering CBT-I. 

Why is this notable?

  1. Recruitment is virtual. 
  2. The hallowed Real World Data (RWD): Engagement, adherence, healthcare utilization, medication utilization, health economic impact, and clinical outcomes in sleep, depression and anxiety in people with chronic insomnia will be evaluated in a real-world environment.
  3. Timely alternative to dependency-inducing insomnia meds: In April, the FDA issued a new warning for several insomnia medications. Having a rigorously validated DTx as an alternative is a welcome move at this time.  

Industry Implications

  1. Quick trials for DTx: This study of 350 participants is due to finish by the end of January 2021. That's under 1 year from the kick off date. Pending meaningful results, this may imply that trials in digital health can be significantly faster when it comes to validating initial assumptions (or expectations?).
  2. Trial continuity during COVID: This is a great example of how we can continue to run trials during COVID by utilizing telehealth and remote monitoring as an alternative to in-person clinic visits. I cannot guesstimate costs, but it's safe to say it'll be cheaper! 
Megan Coder
Megan Coder
Executive Director
Digital Therapeutics Alliance

Megan founded the Digital Therapeutics Alliance and is bullish about the need for rigor in evidence generation and regulation by DTx solutions.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

CVS Pharmacy's New App for the Visually Impaired

Snapshot of the story 

CVS Pharmacy launched a new app, SpeakRx, which can read prescription labels out loud for the visually impaired. This essentially provides an audible label that reads important information including patient name, medication name, dosage and directions aloud in either English or Spanish. This new tool will help ensure that visually impaired patients are taking the correct prescriptions and as prescribed.  

Why It is Notable

Technology and Ophthalmology are striking up a friendship. Even though it is a late entrant to the digital health space, digital ophthalmology solutions are slowly but surely demonstrating potential to support patients with eye conditions  - whether it is novel POC diagnostics, or remote, mobile based visual acuity tests.  

Designing for marginalized groups: Whether it is social, economic or pathological, there seem to be certain groups that we fail to recognize to design our products and services for, and this is a step in the right direction to ensure people with visual impairment adhere to their meds.  

Industry Implications

Integration first: SpeakRx integrates with Siri or Google Assistant to read out prescription instructions.  

Slow adoption: The SpeakRx app is being rolled out in CVS outlets across the country, but it will be just the end of 2021 when the roll out phase is expected to be complete. Seems like a long time to make an app available across the country, isn't it, especially in the context of wide dissemination of mhealth during COVID? 


Kellee M. Franklin, PhD
Kellee M. Franklin, PhD
Strategic Innovation Leader
Mindful Innovation Labs

Kellee is passionate about user centric design and building products and services that truly meet the consumer/patient where they are, at a time they need it, and what they need it for.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

Ready to read more? HealthXL members can access the full peak of the report on the HealthXL Community Hub.

Not yet a member of HealthXL? Download your 11 page snapshot of the report.

Download your 11 page snapshot

Connect with peers and share insights

Don't miss out on the discussion of the latest insights and reports on digital health. Meet with peers and take a deep dive for 75 minutes. Unlike at webinars, you can freely exchange experiences and insights to solve challenges and design the future of DTx.

Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Best routes to market for DTx in the EU

18th October @ 10:45AM EDT

Join us as we discuss the best routes to market for DTx in the EU. These 75 minute sessions are guaranteed to be filled with interesting debate and valuable insights, apply now to secure your place.

Featuring
Giuseppe Recchia
Giuseppe Recchia
Co-Founder & CEO, daVinci Digital Therapeutics
Nemanja Kovačev
Nemanja Kovačev
Digital Health Lead, Syrmia
Featuring
Giuseppe Recchia
Giuseppe Recchia
Co-Founder & CEO, daVinci Digital Therapeutics
Nemanja Kovačev
Nemanja Kovačev
Digital Health Lead, Syrmia
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Companion DTx: clinical & economic evidence

20th October @ 10:45AM EDT

Join our Digital Health Meeting focused on Companion DTx: clinical and economic evidence. This informal conversation brings a variety of stakeholders together to discuss and share their thoughts and experiences around this topic.

Featuring
Jordan Silberman, MD, PhD
Jordan Silberman, MD, PhD
Director of Clinical Analytics and Research, Digital Care Delivery, Anthem, Inc.
Céline Ulmann
Céline Ulmann
Head of R&D Digital, Almirall
Featuring
Jordan Silberman, MD, PhD
Jordan Silberman, MD, PhD
Director of Clinical Analytics and Research, Digital Care Delivery, Anthem, Inc.
Céline Ulmann
Céline Ulmann
Head of R&D Digital, Almirall
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

DTx last mile delivery - HCPs and patients adoption

2nd November @ 11:45AM EDT

Join us in this informal conversation where we will discuss the main challenges around HCP and Patient adoption of DTx. Apply now to connect with peers and learn from fellow thought leaders in this space.

Featuring
Shrawan Patel
Shrawan Patel
Founder & MD, Strategy Health
Céline Ulmann
Céline Ulmann
Head of R&D Digital, Almirall
Featuring
Shrawan Patel
Shrawan Patel
Founder & MD, Strategy Health
Céline Ulmann
Céline Ulmann
Head of R&D Digital, Almirall
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Tech Giants, Start-ups or Incumbents, who will disrupt healthcare?

4th November @ 11:30AM EDT

Join our Digital Health Meeting as discuss How do we define disruption in the healthcare industry? What is the ‘extinction event’ healthcare needs and why has it not happened yet? And what are the learnings from Tech Giants’ moves in healthcareApply now to join the conversation and share your thoughts on the topic.

Featuring
Amanda Goltz
Amanda Goltz
Principal, Business Development, Alexa Health & Wellness at Amazon
Conor Hayes
Conor Hayes
Healthcare Lead, Techvie Software
Featuring
Amanda Goltz
Amanda Goltz
Principal, Business Development, Alexa Health & Wellness at Amazon
Conor Hayes
Conor Hayes
Healthcare Lead, Techvie Software

Are you a HealthXL Member? See the Full Report Here

Non-HealthXL Member? You can purchase the report HERE

HealthXL Digital Health Meetings

Want to join the discussion now?

Join our Digital Health Meetings and take a deep dive for 75 minutes into topics like digital therapeutics, patient support, telehealth, clinical trials, dermatology and many more. These Meetings are not regular webinars: No audience, no recording and no hiding behind a screen. You actively participate in a discussion to solve your present challenges and design the future of digital health. And with a free account on our Community Hub, you stay connected and up-to-date on the latest news and insights, allowing you to fully immerse yourself in the topic before, during and after.

Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Best routes to market for DTx in the EU

18th October @ 10:45AM EDT

Join us as we discuss the best routes to market for DTx in the EU. These 75 minute sessions are guaranteed to be filled with interesting debate and valuable insights, apply now to secure your place.

Featuring
Giuseppe Recchia
Giuseppe Recchia
Co-Founder & CEO, daVinci Digital Therapeutics
Nemanja Kovačev
Nemanja Kovačev
Digital Health Lead, Syrmia
Featuring
Giuseppe Recchia
Giuseppe Recchia
Co-Founder & CEO, daVinci Digital Therapeutics
Nemanja Kovačev
Nemanja Kovačev
Digital Health Lead, Syrmia
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Companion DTx: clinical & economic evidence

20th October @ 10:45AM EDT

Join our Digital Health Meeting focused on Companion DTx: clinical and economic evidence. This informal conversation brings a variety of stakeholders together to discuss and share their thoughts and experiences around this topic.

Featuring
Jordan Silberman, MD, PhD
Jordan Silberman, MD, PhD
Director of Clinical Analytics and Research, Digital Care Delivery, Anthem, Inc.
Céline Ulmann
Céline Ulmann
Head of R&D Digital, Almirall
Featuring
Jordan Silberman, MD, PhD
Jordan Silberman, MD, PhD
Director of Clinical Analytics and Research, Digital Care Delivery, Anthem, Inc.
Céline Ulmann
Céline Ulmann
Head of R&D Digital, Almirall
AI in Healthcare
AI in Healthcare
AI in Healthcare
AI in Healthcare

Masterclass: AI-based diagnostics - learnings from a real-world use case

21st October @ 9:00AM GMT

In this masterclass, Zachary Tan (Advisor at CancerAid; Venture Creation Partner at Aegis Ventures; more info here) & Lisa Zhu (Research Fellow of the Center for Eye Research Australia) will walk us through the key learnings from their latest article in Scientific Reports (Nature) on real-world AI-based screening for diabetic retinopathy in Australia. This early-stage study is one of the first globally to describe the real-world implementation of AI in healthcare.

Featuring
Zachary Tan
Zachary Tan
Venture Creation Partner, Aegis Ventures
Lisa Zhu
Lisa Zhu
Research Fellow, CERA
Featuring
Zachary Tan
Zachary Tan
Venture Creation Partner, Aegis Ventures
Lisa Zhu
Lisa Zhu
Research Fellow, CERA
Digital Mental Health & Neurology
Digital Mental Health & Neurology
Digital Mental Health & Neurology
Digital Mental Health & Neurology

Digital Health in Mental Health: Commercialization Models

21st October @ 10:45AM EDT

Join us in this informal conversation where we will discuss the best commercialisation models for digital companies in the mental health space. Our 75 minute sessions are guaranteed to be filled with interesting debate and great conversation.

Featuring
Robert Garber
Robert Garber
Partner, 7Wire Ventures
Sarah Fisher
Sarah Fisher
Senior Director, Global Markets, External Innovation, Johnson & Johnson Medical Devices
Featuring
Robert Garber
Robert Garber
Partner, 7Wire Ventures
Sarah Fisher
Sarah Fisher
Senior Director, Global Markets, External Innovation, Johnson & Johnson Medical Devices

What’s a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.